Annals of Clinical Biochemistry > Volume 40, Number 6 > Pp. 612-627

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lips, C. J. Articles by Höppener, J. W. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Review Articles

The spectrum of carcinoid tumours and carcinoid syndromes

Cornelis JM Lips, Eef GWM Lentjes and Jo WM Höppener

Department of Clinical Endocrinology, University Medical Center Utrecht, POB 85500, 3508 GA Utrecht, The Netherlands; Department of Laboratory Endocrinology, University Medical Center Utrecht, POB 85500, 3508 GA Utrecht, The Netherlands; Department of Clinical Endocrinology, University Medical Center Utrecht, POB 85500, 3508 GA Utrecht, The Netherlands

Carcinoids are neuroendocrine tumours of the gut which may also be found in the bronchus, pancreatic islets and retroperitoneum. They probably arise from gastrointestinal or bronchopulmonary pluripotential stem cells. Carcinoid tumours derived from these cells are potentially malignant; the strength of the tendency for aggressive growth correlates with the site of origin, depth of local penetration and the size of the tumour. Carcinoids occur sporadically or result from specific hereditary tumour syndromes. Mutations and/or aberrant expression of specific genes induce and promote tumour growth. Clinical features include local symptoms due to angulation or obstruction and hepatomegaly due to liver metastases.

The carcinoid syndrome commonly involves flushing, diarrhoea, bronchospasm and hypotension. Other distinct syndromes may be caused by tumour release of products that may also be used as biochemical markers in diagnosis and follow-up. Scanning using radiolabelled octreotide, an analogue of somatostatin, sensitively identifies occult primary and metastatic deposits.

Localized carcinoid tumours should be resected. Some patients benefit from hepatic resection. Palliation of symptoms is best achieved with octreotide. Hepatic artery chemoembolization may produce long-acting palliation.

Further genetic characterization of the different types and stages of carcinoid development as well as assessment of gene expression profiles may improve differential diagnosis, prognosis and treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?